Mesenchymal Stem Cells Market to Register Remarkable Growth due to Favorable Reimbursement Policies, Global Industry Report, Size Estimation, Share, Analysis, Top Companies Revenues

Overview:

Mesenchymal stem cells (MSC), are adult stem cells that are isolated from various sources that can differentiate into other types of cells. These cells were isolated first time from the bone marrow and then from other different sources like adipose tissue, cord cells, and molar cells. Mesenchymal stem cells are smaller in size and observing them in histological sections is difficult. A group of MSCs is known as mesenchyme, which is widely spread in the body. These cells can grow in numerous specialize cells in in-vivo or in-vitro conditions. The MSCs have a key role in various functions within an organism such as suppression of immune cell activation, lower cell death or damage in the body, increasing the number of newer cells and secretion of angiogenic and neurotrophic factors. Any blood vessel in the cerebrum brain that is damaged can be repaired or replaced with the mesenchymal cells.

Request Here For FREE PDF Brochure 

Drivers:

Increasing cases of osteoporosis and cancer are expected to propel growth of the global Mesenchymal stem cells market during the forecast period. For instance, in 2015, as per the National Institute of Health (NIH), 53 million people were suffering from osteoporosis in the U.S.

Furthermore, Osteoporosis Canada reported that osteoporosis fracture affects 1 in 3 women and 1 in 5 men throughout their lifetime, and it is responsible for around 70 to 90% of 30,000 hip fractures. In 2012, the annual cost of osteoporosis treatment was around US$ 4.0 billion in Canada, and it is likely to increase in the future.

As per the International Osteoporosis Foundation (IOF), about 9.0 million individuals suffer from osteoporosis fracture globally.

Regional analysis:

Among regions, North America and Asian Pacific are expected to witness strong growth followed by Europe in the mesenchymal stem cells market, owing to increasing technological development, well-resourced healthcare centers, and high disposable incomes. For instance, in 2018, the World Health Organization (WHO) estimated 9.6 million deaths were caused by cancer all over the world making it the second leading cause of mortality worldwide.

Moreover, in 2018, as per the European Journal of Cancer, cancer affected over 3.9 million people and caused 1.9 million deaths in Europe.

While in 2012, National Center for Biotechnology Information (NCBI) stated that 18.0% of females were affected by breast cancer and caused 9% of deaths in Asia Pacific making it the fourth leading cause of death in the region.

Market Taxonomy:

By product type:

• Human MSCs

• Mouse MSCs

• Rat MSCs

• Others

By application:

• Drug discovery and development

• Injuries

• Cardiovascular and myocardial infarction

• Others

By region:

• North America

• Latin America

• Europe

• Asia Pacific

• Middle East  

• Africa

Key developments:

Market players are adopting various strategies such as collaborations, acquisition as well as launch of new products to increase their R&D activities and regional presence. For instance, in February 2019, Pluristem Therapeutics and Ames Research Center of NASA collaborated to assess the efficiency of Pluristem’s PLX cell therapies in the treatment and prevention of medical conditions occurred in space operations.

Request For Sample Copy  

Moreover, in February 2019, BrainStorm Cell Therapeutics Inc. expanded its clinical trial facility in Cleveland Clinic as the first U.S. clinical site for Phase 2 open-label, multicenter study of repeated intrathecal administration of autologous mesenchymal stem cells secreting neurotrophic factors (MSC-NTF) in participants with progressive Multiple Sclerosis (MS).

In February 2019, Cytonus Therapeutics announced the development of Cargocytes, which is a first controllable, cell-based platform technology that delivers biologics.

Major players:

major market players active in the mesenchymal stem cells market include, LonzaThermo, ATCC, MilliporeSigma, Celprogen, PromoCell GmbH, Axol Bioscience, Eutilex Co.Ltd., ID Pharma Co. Ltd., Cytori Therapeutics Inc., Angel Biotechnology, California Stem Cell Inc., Celgene Corporation Inc., Pluristem Therapeutics, Fisher, Bio-Techne, Genlantis, Cell Applications, Cyagen Biosciences, Human Longevity Inc., Cytori Therapeutics, BrainStrom Cell Therapeutics, Neovii Biotech, and Stemcelltechnologies Inc.

Buy This Premium Report 

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Mesenchymal Stem Cells Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Mesenchymal Stem Cells Industry Impact

Chapter 2 Global Mesenchymal Stem Cells Competition by Types, Applications, and Top Regions and Countries
2.1 Global Mesenchymal Stem Cells (Volume and Value) by Type
2.3 Global Mesenchymal Stem Cells (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Mesenchymal Stem Cells Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Mesenchymal Stem Cells Market Analysis
Chapter 6 East Asia Mesenchymal Stem Cells Market Analysis
Chapter 7 Europe Mesenchymal Stem Cells Market Analysis
Chapter 8 South Asia Mesenchymal Stem Cells Market Analysis
Chapter 9 Southeast Asia Mesenchymal Stem Cells Market Analysis
Chapter 10 Middle East Mesenchymal Stem Cells Market Analysis
Chapter 11 Africa Mesenchymal Stem Cells Market Analysis
Chapter 12 Oceania Mesenchymal Stem Cells Market Analysis
Chapter 13 South America Mesenchymal Stem Cells Market Analysis
Chapter 14 Company Profiles and Key Figures in Mesenchymal Stem Cells Business
Chapter 15 Global Mesenchymal Stem Cells Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology